Toxicologic Pathology Forum: Considerations Regarding Determination of Adversity for Immunopathology Findings in Nonclinical Toxicology Studies with Immune-Modulating Therapeutics.

Papenfuss, Tracey L; Himmel, Lauren; Kuper, C Frieke; Mohanan, Sunish; Harleman, Johannes; Elmore, Susan A

Papenfuss, Tracey L; Himmel, Lauren; Kuper, C Frieke; Mohanan, Sunish; Harleman, Johannes; Elmore, Susan A.

Afiliação

Papenfuss TL; StageBio, Mount Jackson, Virginia, USA.
Himmel L; AbbVie Inc., North Chicago, Illinois, USA.
Kuper CF; Independent Consultant, Utrecht, The Netherlands.
Mohanan S; Gilead Sciences, Foster City, California, USA.
Harleman J; Independent Consultant, Darmstadt, Germany.
Elmore SA; ElmorePathology LLC, Chapel Hill, North Carolina, USA.

Toxicol Pathol ; 51(4): 205-215, 2023 06.

Article em En | MEDLINE | ID: mdl-37578155

Palavras-chave

adversity; immune system; immunomodulatory; immunosafety; immunotoxicology; nonclinical; preclinical

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article